ImmunityBio, Inc.IBRXEarnings & Financial Report
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Revenue
$26.4M
Gross Profit
$26.3M
Operating Profit
$-71.3M
Net Profit
$-92.6M
Gross Margin
99.5%
Operating Margin
-269.8%
Net Margin
-350.3%
YoY Growth
2423.9%
EPS
$-0.10
ImmunityBio, Inc. Q2 FY2025 Financial Summary
ImmunityBio, Inc. reported revenue of $26.4M (up 2423.9% YoY) for Q2 FY2025, with a net profit of $-92.6M (up 31.2% YoY) (-350.3% margin). Cost of goods sold was $136.0K, operating expenses totaled $97.6M.
Key Financial Metrics
| Total Revenue | $26.4M |
|---|---|
| Net Profit | $-92.6M |
| Gross Margin | 99.5% |
| Operating Margin | -269.8% |
| Report Period | Q2 FY2025 |
ImmunityBio, Inc. Annual Revenue by Year
ImmunityBio, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $113.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $113.3M |
ImmunityBio, Inc. Quarterly Revenue & Net Profit History
ImmunityBio, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $38.3M | +407.0% | $-61.9M | -161.8% |
| Q3 FY2025 | $32.1M | +425.1% | $-67.3M | -209.8% |
| Q2 FY2025 | $26.4M | +2423.9% | $-92.6M | -350.3% |
| Q1 FY2025 | $16.5M | +41192.5% | $-129.6M | -784.9% |
| Q4 FY2024 | $7.6M | +5333.1% | $-59.2M | -783.4% |
| Q3 FY2024 | $6.1M | +7346.3% | $-85.7M | -1404.0% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.1M | $7.6M | $16.5M | $26.4M | $32.1M | $38.3M |
| YoY Growth | 7346.3% | 5333.1% | 41192.5% | 2423.9% | 425.1% | 407.0% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Assets | $364.6M | $382.9M | $303.8M | $402.1M | $519.0M | $501.9M |
| Liabilities | $1.11B | $871.1M | $894.2M | $971.9M | $1.04B | $1.00B |
| Equity | $-745.1M | $-489.1M | $-591.4M | $-570.7M | $-524.3M | $-500.5M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-98.8M | $-85.1M | $-85.9M | $-79.7M | $-68.9M | $-70.4M |